Compare DAIO & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | PLUR |
|---|---|---|
| Founded | 1969 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1M | 28.4M |
| IPO Year | N/A | N/A |
| Metric | DAIO | PLUR |
|---|---|---|
| Price | $3.16 | $3.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.22 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 14.8K | 9.6K |
| Earning Date | 02-26-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,701,000.00 | $1,326,000.00 |
| Revenue This Year | $7.87 | $97.38 |
| Revenue Next Year | $0.79 | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 121.74 |
| 52 Week Low | $1.88 | $2.82 |
| 52 Week High | $3.57 | $7.13 |
| Indicator | DAIO | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 58.08 |
| Support Level | $3.05 | $3.30 |
| Resistance Level | $3.20 | $3.50 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 52.78 | 81.37 |
Data I/O Corp is a provider of programming, security deployment, security provisioning, and associated Intellectual Property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices, and secure microcontrollers. It is engaged in focused on the design, manufacturing and sale of programming systems used by designers and manufacturers of electronic products. It has its geographic presence in the United States, Europe, and Asia and others. The company derives the majority of its revenue from Asia and others.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.